Table 1.
Patient characteristics
| Number | Percentage | |
| Gender | ||
| Male | 32 | 82% |
| Female | 8 | 18% |
| ECOG performance status1 | ||
| 0 | 21 | 55% |
| 1 | 14 | 37% |
| 2 | 3 | 8% |
| Etiology of hepatocellular carcinoma2 | ||
| Hepatitis C | 17 | 46% |
| Alcohol | 8 | 22% |
| Combination of Hepatitis C/alcohol | 8 | 22% |
| NASH | 4 | 8% |
| BCLC Stage | ||
| 0 (very early) | 6 | 15% |
| A (early) | 10 | 25% |
| B (intermediate) | 24 | 60% |
| Previous treatment | ||
| None | 34 | 85% |
| TACE | 6 | 15% |
| Number of treated lesions | ||
| Single | 32 | 80% |
| Multiple3 | 8 | 20% |
| Initial MELD score | ||
| < 10 | 31 | 78% |
| > 10 | 9 | 22% |
| Median tumor size (range) | 3.5 cm | (1.5 to 8.9 cm) |
| Median gross tumor volume (range) | 23 cc | (2.6 to 220.1 cc) |
| Median planning target volume (range) | 67.6 cc | (11.5 to 351 cc) |
1
2 patients unknown;
2
1 patient with biliary cirrhosis and 1 immunosuppressed;
3
7 patients with 2 lesions and 1 with 3 lesions. ECOG: Eastern cooperative oncology group; NASH: Non-alcoholic steatohepatitis; BCLC: Barcelona liver clinic; TACE: Transarterial chemo-embolization; MELD: Model for end stage liver disease.